医学
膀胱癌
HMG-CoA还原酶
生物标志物
他汀类
泌尿系统
内科学
泌尿科
卡介苗
队列
羟甲基戊二酰辅酶A还原酶抑制剂
癌症
肿瘤科
还原酶
病理
化学
酶
接种疫苗
生物化学
作者
Jamie Krishnan,Andrew Symington,Neil M. Kernohan,Susan E. Bray,A J Robertson,Ghulam Nabi
标识
DOI:10.1177/00369330231213935
摘要
Background Cardiovascular disease affects over 7 million people in the UK and statins are often prescribed to mitigate cardiovascular risks. The effect of statins on a number of cancers is debated and their effect on Bacillus Calmette-Guérin (BCG) responsiveness in non-muscle invasive urinary bladder cancer (NMIBC) is not fully understood. Aims This study aims to explore the difference in HMG Co-A reductase (HMGCR) expression in NMIBC on immunochemistry in BCG responders and non-responders while on statins. Method Three hundred and thirty-two cases of intravesical BCG treatment for high-risk NMIBC between November 2003 and December 2017 were identified. Patients taking statins for at least 12 months before the diagnosis of NIMBC and with a follow-up of at least 5 years were included. They were divided into BCG responders and non-responders. Tumour tissue from these patients was immunohistochemically stained and quantitative image analysis carried out to assess and compare HMGCR expression in the groups. Results & Conclusion This study showed a differential expression of HMGCR in responders vs. non-responders to BCG for high-risk NMIBC on statins. This data should form the basis of a further research and multi-centre study in a larger cohort, using HMGCR as a biomarker of response in patients on statins.
科研通智能强力驱动
Strongly Powered by AbleSci AI